Dyslipidemia - Statins Dominate Treatment Pathway

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-10-05

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor estimates that there are 267m people in the seven major markets with total cholesterol >200mg/dL which is set to rise to 287m in 2015. Despite this vast patient potential, low diagnosis rates limit the market size, and with the launch of generic statins, and the maturing of the market, it is increasingly important for companies to target the under-treated dyslipidemia sub-populations.


Scope

  • 180 physician interviews carried out across the seven major pharmaceutical markets, plus the views of key industry opinion leaders
  • Examination of dyslipidemia patient potential, detailing the current and future prevalence of high total cholesterol
  • Detailed treatment trees to show dyslipidemia patient flows at country levels (US, Japan, France, Germany, Italy, Spain and the UK)
  • Expected future prescribing rates for combination therapy and new agents, such as Vytorin (ezetimibe + simvastatin) and atorvastatin and torcetrapib


    • Report Highlights
    Dyslipidemia patients are often plagued with risk factors and co-morbidities that increase their relative risk considerably. Datamonitor research found that a high percentage of patients with dyslipidemia also suffer from obesity, hypertension and type 2 diabetes, representing a potentially lucrative target.

    The more aggressive approach to LDL lowering, and lower treatment thresholds recommended in updated guidelines means a greater patient population. However, increasing awareness in physicians and in the general population is essential to increase diagnosis and thus treatment rates.

    Physicians predict that combination therapy will play an increasingly important role over the next three years. Given the highly competitive nature of the antidyslipidemic market, companies that can position novel products as effective treatments for use in combination therapy are likely to be the most successful.


    Reasons to Purchase

  • Gain independent insight into the management of dyslipidemia and understand what factors influence physicians' prescribing practices
  • Assess the future direction of dyslipidemia therapy, and the remaining unmet needs in order to successfully manage your developmental products
  • Identify lucrative new target populations in order to create new opportunities in this market

    • Table of Contents

    Other users found this report page using the following search terms: Dyslipidemia Antidyslipidemia Antidyslipidemic obesity cholesterol segmentation statins what dyslipidemia mixed dyslipidemiaunmet needs

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.